Methotrexate

Basic Methotrexate Information

• INN (International Nonproprietary Name): Methotrexate.
• Brand Names Available In United Kingdom: Jylamvo; Maxtrex; Metex / Metoject; Nordimet; Ledertrexate (other global brands listed but UK-specific availability not specified).
• ATC Code: L01BA01.
• Forms & Dosages: Oral tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg; Oral solution 2 mg/ml and 2.5 mg/ml; Injection (vial or ampoule) 10 mg/ml and 25 mg/ml.
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: not specified.

Critical Warnings & Restrictions

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Methotrexate is a high‑risk prescription medicine and requires careful counselling before and during treatment.

Patients must receive written and verbal information about fertility and pregnancy avoidance because methotrexate is teratogenic.

Breastfeeding should be avoided while taking methotrexate unless a specialist advises otherwise.

Strict monitoring of liver, renal and haematological function is mandatory for safe treatment.

• Chronic liver disease or significant alcohol use increases hepatotoxic risk.
• Significant renal impairment reduces methotrexate clearance and increases toxicity risk.
• Active infections or immunosuppression raise the risk of severe infection.
• Reduced bone‑marrow reserve or pre‑existing cytopenias demand specialist input and dose adjustment.
• Elderly patients often require lower starting doses and closer blood monitoring.

Healthcare staff must follow MHRA guidance and record informed consent where fertility or pregnancy risks apply.

Patients should carry a patient alert card and be ready to report serious symptoms immediately.

• Checklist for Pregnancy Prevention:
• Confirm effective contraception for women of childbearing potential before starting.
• Advise men and women about contraception requirements during therapy and for the recommended washout period after stopping, as directed by the specialist.
• Arrange pregnancy testing where clinically appropriate before initiation.

• Checklist For Immediate Reporting:
• Fever or signs of infection.
• Mouth ulcers or severe oral soreness.
• Severe diarrhoea or vomiting.
• Unexplained bruising, bleeding, or breathlessness.
• Always carry the patient alert card and contact the clinic or pharmacist immediately if any of these occur.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Some people experience dizziness, drowsiness or visual disturbance when taking methotrexate.

Patients should assess their ability to drive or operate machinery after dosing and until they know how it affects them.

Employers should be informed if the patient’s role involves safety‑critical tasks or heavy machinery.

Pharmacists should include driving and workplace safety advice during counselling and advise on DVLA responsibilities for safety‑critical roles when applicable.

Q&A — “Can I Drive After Taking It In The UK?”

Short answer: usually yes if you feel well and are not experiencing side effects that impair driving.

Methotrexate can cause dizziness, drowsiness or visual disturbance in some people.

Under UK driving law, patients must ensure they are safe to drive and must not drive if impaired.

If impaired, do not drive and seek clinical advice promptly.

If your clinician advises you to inform the DVLA because your condition or treatment affects driving, follow that advice.

• Immediate Actions If You Feel Unwell After Dosing:
• Stop driving and find a safe way home.
• Contact your prescriber or pharmacist for advice.
• Record symptoms and follow up at the next clinic or blood test as advised.

Usage Basics

INN, Brand Names Available In The UK

Methotrexate is the International Nonproprietary Name used on UK prescriptions.

Common brands mentioned in product information and available in EU/UK supply lines include Jylamvo, Maxtrex and Metex / Metoject.

Nordimet is also listed as a prefilled syringe option in the EU market and may appear in UK formularies depending on supply.

Generic methotrexate tablets remain widely used across NHS settings due to cost‑effectiveness.

Legal Classification (POM, P, GSL)

Methotrexate is a Prescription‑Only Medicine in the UK and must be supplied on a valid prescription.

Pharmacists must follow MHRA and NHS rules, provide counselling and supply the relevant patient information leaflet with each supply.

INN

Methotrexate.

ATC Code

L01BA01.

Brand Examples

Jylamvo; Maxtrex; Metoject; Nordimet.

• Available Forms: methotrexate tablets, methotrexate oral liquid and methotrexate injection.

Dosing Guide

Standard Regimens (NHS Guidelines)

Dosing depends on the indication and is always prescribed by a clinician familiar with methotrexate monitoring.

• Rheumatoid arthritis and psoriasis: low‑dose weekly regimens are standard, commonly 7.5–25 mg once weekly, given orally or subcutaneously.
• Paediatric and swallowing‑difficulty patients may receive oral liquid formulations such as Jylamvo or Xatmep at clinician‑directed doses.
• Oncology regimens use much higher doses and different schedules under secondary care protocols and are not managed in primary care.

NHS guidance emphasises the critical rule that methotrexate for inflammatory conditions must be dosed weekly to avoid potentially fatal daily dosing errors.

Baseline tests before initiation should include a full blood count, liver function tests and renal function, with ongoing monitoring thereafter.

Folic acid supplementation is routinely prescribed to reduce mucosal and hepatic adverse effects.

• Monitoring Checklist:
• Baseline FBC, LFTs, renal function and, where indicated, chest X‑ray or viral hepatitis screening.
• Repeat FBC, LFTs and renal function at intervals set by the clinic, commonly every 1–3 months initially.
• More frequent checks after dose changes or if adverse symptoms occur.

Adjustments For Comorbidities

Renal impairment, hepatic disease, low body weight and advanced age often require reduced doses or specialist review.

Clinicians should consider dose reduction or alternative therapy where significant comorbidity raises the risk of toxicity.

Q&A — “What If I Miss A Dose?”

Short answer: do not double up on doses.

If a weekly dose is missed by only a few days, the prescriber or pharmacist may advise taking it as soon as remembered or skipping to the next scheduled week depending on clinical factors.

Always contact the prescriber or pharmacist for tailored advice rather than making an independent decision to double the dose.

Interaction Chart

Food And Drinks (Alcohol, Tea/Coffee, Diet Habits)

Alcohol increases the risk of hepatotoxicity with methotrexate and should be minimised or avoided as advised by the prescriber.

High‑dose vitamin supplements such as very large doses of vitamin C can alter elimination in theory; standard multivitamins are not routinely contraindicated but discuss any large or concentrated supplements with the clinic.

Good hydration supports renal elimination and helps reduce toxicity risk.

Caffeine from tea or coffee does not have a major direct interaction but avoid dehydration when consuming diuretics or during illness.

Common Drug Conflicts (MHRA Yellow Card Data)

Several medicines can increase methotrexate toxicity or reduce its elimination; pharmacy review of all concurrent medicines is essential.

• Trimethoprim can potentiate bone‑marrow suppression.
• NSAIDs may reduce renal clearance and raise methotrexate levels; review OTC NSAID use with the patient.
• Certain penicillins and proton‑pump inhibitors have been implicated in altered elimination.
• Concurrent immunosuppressants increase infection risk.

Pharmacists should consult the MHRA Yellow Card database when reviewing adverse reaction reports and must review over‑the‑counter NSAID use with every supply.

Promptly refer to the prescriber or specialist if an interacting medication is required for the patient.

For further spontaneous reports and pharmacovigilance signals, consult the MHRA Yellow Card online resource.

User Reports & Trends

Insights From NHS Choices, Patient.info And Mumsnet Forums

Patients commonly report good symptom control on low‑dose weekly methotrexate for inflammatory conditions.

Typical side effects discussed in forums include gastrointestinal upset, fatigue and mouth ulcers.

Fertility concerns and long‑term liver safety are frequent topics of patient concern and discussion.

There is a noticeable trend towards greater uptake of subcutaneous delivery devices such as Metoject and Nordimet, and oral liquids like Jylamvo for patients who have difficulty swallowing tablets.

Online communities often emphasise the value of clear pharmacist counselling, explicit confirmation of weekly dosing and easy access to blood test results.

• Common Patient Concerns:
• Will methotrexate affect fertility or pregnancy?
• How soon will blood tests show problems?
• What are safe alcohol limits?
• Can injections be done at home and how is sharps disposal arranged?

Clinicians should balance anecdotal patient reports with formal clinical evidence and MHRA safety communications when advising patients.

Access & Purchase Options

Boots, LloydsPharmacy, Superdrug

Methotrexate is dispensed on NHS prescriptions, whether electronic or paper, or on private prescriptions where applicable.

High‑street chains such as Boots, LloydsPharmacy and Superdrug routinely dispense methotrexate and provide pharmacist counselling at collection.

Community pharmacists typically access NHS electronic prescriptions and Summary Care Records to check interactions and monitoring history before supply.

Online Pharmacies And NHS E‑Prescriptions

Registered online pharmacies may supply methotrexate with a valid prescription and must provide pharmacist counselling before supply.

In England a per‑item prescription charge usually applies unless the patient is exempt, while Scotland, Wales and Northern Ireland generally provide free prescriptions.

• Checklist For Verifying An Online Pharmacy:
• Confirm MHRA or GPhC registration and valid UK pharmacy address.
• Ensure pharmacist counselling is offered before supply.
• Check prescription handling and privacy policies.

In our online pharmacy, methotrexate is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

Methotrexate is a folic acid analogue that inhibits dihydrofolate reductase and interferes with DNA synthesis and cellular replication.

At low weekly doses used in rheumatology and dermatology, immunomodulatory effects predominate rather than cytotoxic effects.

High oncology doses exert direct cytotoxic effects and require inpatient or specialist management.

Oral absorption is variable and may fall at higher tablet doses, while subcutaneous administration offers more predictable bioavailability.

Renal excretion is the primary elimination route, making renal function a key determinant of safety.

Clinical Terms

ATC Classification

L01BA01 — antineoplastic and immunomodulating agent, folic acid analogue.

Folinic Acid Rescue

Used in high‑dose methotrexate or overdose situations to reduce toxicity.

Bioavailability Notes

Oral tablets may have lower and variable bioavailability compared with subcutaneous preparations such as Metoject and Nordimet.

Indications & Off‑Label Uses

MHRA‑Approved Uses

Methotrexate is authorised for certain malignancies and for a range of autoimmune and inflammatory conditions in specified formulations and doses.

Low‑dose weekly methotrexate is commonly used across the NHS for rheumatoid arthritis, severe psoriasis and some inflammatory arthropathies as part of standard practice.

Off‑Label Practices In NHS And Private Care

Off‑label use is sometimes considered where evidence supports benefit and informed consent has been obtained.

• Common Off‑Label Or Specialist Uses:
• Certain dermatological disorders when other treatments have failed.
• Ocular inflammatory disease under specialist supervision.
• Steroid‑sparing therapy in selected inflammatory conditions.

Shared‑care agreements between hospital specialists and GPs are a common method for managing prescribing and monitoring responsibilities for chronic therapy.

Contraception and pregnancy avoidance must be discussed and documented regardless of indication.

Key Clinical Findings

Recent UK and EU research between 2022 and 2025 focuses on optimising route, dosing and monitoring to improve outcomes and safety.

Comparative trials indicate that subcutaneous methotrexate (for example via Metoject or Nordimet) can provide better bioavailability and symptom control for some patients compared with oral tablets, reducing the need for dose escalation.

Studies on folic acid dosing aim to strike a balance between reducing hepatotoxicity and cytopenias while maintaining clinical efficacy.

Real‑world registry analyses highlight the importance of renal monitoring to prevent serious adverse events and support personalised dosing in older adults.

Cost‑effectiveness analyses in NHS settings commonly favour generic oral methotrexate for many patients, while auto‑injectors and oral liquids (such as Jylamvo) provide clear advantages for adherence or swallowing difficulties in selected patients.

All findings should be interpreted alongside MHRA safety notices and local formulary guidance when making prescribing decisions.

Alternatives Matrix

NHS Prescribing Alternatives (Comparison Table)

Pros And Cons Checklist

• Assess efficacy versus monitoring burden for each option.
• Consider teratogenicity and required contraception (notably with leflunomide and methotrexate).
• Review infection risk, especially when combining immunosuppressants or switching to biologics.
• Consider cost and formulary status; generic options may reduce NHS expenditure.
• Document shared decision‑making and adhere to local formulary guidance.

Common Questions

• Will methotrexate affect fertility or pregnancy plans?
• Methotrexate is teratogenic and contraception is mandatory for men and women as advised by the specialist; stopping periods must be planned with the clinic.
• How often will I need blood tests?
• Baseline tests are required, then typically every 1–3 months depending on stability and local shared‑care protocols; more frequent monitoring follows dose changes or abnormal results.
• Can I drink alcohol?
• Alcohol should be avoided or limited; discuss safe limits with your clinician given increased liver risk.
• Can I take OTC painkillers or supplements?
• Check with the pharmacist before taking OTC NSAIDs or antibiotics, as they can interact; folic acid supplementation is commonly recommended alongside methotrexate.

Provide written information and pharmacist counselling to reinforce clinic advice and ensure safe use.

NHS Cost & Access Comparison Table

Registration & Regulation

MHRA Approval Process

Methotrexate products are authorised via national or EU/UK regulatory procedures and require submission of quality, safety and efficacy data.

Marketing authorisation holders have pharmacovigilance obligations including reporting suspected adverse drug reactions via the Yellow Card scheme.

For parallel‑imported or international brands, pharmacy teams must verify licence status and storage conditions when stocking or supplying.

MAA

Marketing Authorisation Application — the process for product approval.

Pharmacovigilance

Ongoing safety monitoring by manufacturers and regulators; practitioners should report suspected ADRs.

Yellow Card

MHRA spontaneous reporting system for suspected adverse drug reactions.

NHS Prescribing Framework

Shared‑care protocols are common and set out responsibilities between hospital specialists and GPs for initiation, monitoring and routine prescribing.

Electronic prescriptions and Summary Care Records support safe handover and help pharmacists check monitoring status before supply.

Community pharmacists must follow MHRA safety communications and confirm weekly dosing prior to supply.

Storage & Handling

UK Household Storage (Cold/Damp Climate)

Store methotrexate according to the product leaflet.

Most oral tablets and oral solutions are stored at room temperature and should be protected from moisture.

Injectable vials or prefilled syringes have product‑specific storage instructions and may require controlled temperatures.

Avoid storing methotrexate in bathrooms or windowsills where humidity and temperature fluctuate.

Keep all medicines out of reach of children and pets, in a cool, dry place.

• Do’s And Don’ts:
• Do follow the product leaflet and expiry dates carefully.
• Do check expiry after opening multi‑dose liquids and store upright if advised.
• Don’t store in humid or hot places such as near radiators or windowsills.
• Don’t keep unused or out‑of‑date methotrexate — arrange safe disposal.

• Safe Disposal Checklist:
• Use local NHS or pharmacy‑run medicine take‑back services for return of unused methotrexate.
• Do not dispose of methotrexate into household waste or drains unless local guidance allows.
• For sharps (used syringes), supply a designated sharps bin and advise on collection or return services.

Guidance From NHS And Pharmacists

Pharmacists should provide written storage advice, clear labelling and reminders about expiry and disposal during counselling.

For accidental significant exposure or spills, follow local SOPs and seek medical advice promptly.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Start counselling by confirming the indication and the exact prescribed dose, explicitly reconfirming the weekly schedule.

Review all concurrent medicines and over‑the‑counter preparations to identify interactions such as NSAIDs or antibiotics.

Assess pregnancy risk and contraception status and ensure appropriate documentation and referral to specialist advice.

Explain folic acid supplementation and advise on alcohol restriction and symptom recognition for urgent reporting.

Use the teach‑back method to confirm the patient can describe when and how to take the weekly dose safely.

• Counselling Checklist:
• Confirm weekly dose and dosing day by name of the day (eg “take on Friday” rather than “once a week”).
• Record current medications and OTC use.
• Check contraception and pregnancy status where applicable.
• Agree monitoring intervals and how the patient will receive blood test results.
• Provide a patient alert card, written leaflet and clear labelling with yellow warning stickers where available.

Short Patient Leaflet Template:

Take methotrexate once weekly on the day agreed with your clinic.

Take folic acid as prescribed to reduce side effects.

Do not take over‑the‑counter NSAIDs without checking with your pharmacist.

Report fever, mouth ulcers, bruising, breathing problems or severe diarrhoea immediately.

Carry your patient alert card and attend blood tests as scheduled.

NHS Patient Safety Advice

Apply clear labelling and use yellow warning stickers to emphasise weekly dosing and reduce accidental daily dosing errors.

Liaise with prescribers if monitoring is overdue or results are abnormal before supply.

For home injections provide practical training, arrange sharps disposal and give emergency contact details for adverse reactions.

Delivery Across United Kingdom